基线与中期[18F]FDG PET代谢参数在儿童霍奇金淋巴瘤中的预后价值
该单中心回顾性研究纳入2016至2023年确诊并接受EuroNet-PHL-C1和DAL/GPOH-HD方案治疗的儿童霍奇金淋巴瘤患者115例,于2周期化疗后行基线与中期PET/CT,评估SUVmax、MTV和TLG对无事件生存期(EFS)的预后价值。中位随访35个月,16例(13.9%)复发或进展;多因素分析显示中期MTV 2.5>0 ml(校正HR 3.89,p=0.009)和中期TLG 41%≥30 g(校正HR 7.98,p=0.006)为EFS的独立危险因素。
要点
- 基线与中期MTV 2.5、MTV 41%、TLG 2.5、TLG 41%及中期SUVmax均与更差EFS显著相关。
- 中期MTV 2.5>0 ml为EFS独立危险因素(校正HR 3.89,p=0.009)。
- 中期TLG 41%≥30 g为EFS独立危险因素(校正HR 7.98,p=0.006)。
核心结论
- 基线与中期[18F]FDG PET参数可作为儿童霍奇金淋巴瘤EFS和治疗反应的重要预后指标。
- 这些定量指标可能有助于优化儿童和青少年霍奇金淋巴瘤的个体化、风险适应治疗策略。
研究设计与样本
- 单中心、回顾性研究,纳入2016至2023年确诊的儿童霍奇金淋巴瘤患者,按EuroNet-PHL-C1和DAL/GPOH-HD方案治疗。
- 患者接受基线与2周期化疗后中期PET/CT,采用SUV 2.5和41% SUVmax两种分割方法评估SUVmax、MTV和TLG。
- 主要终点为无事件生存期(EFS),次要终点为Deauville评分,采用Cox回归分析评估生存结局。
- 共纳入115例患者(男性50例,中位年龄14.2岁),中位随访35个月。
主要发现
- 随访期间16例(13.9%)出现复发或进展。
- 基线与中期MTV 2.5、MTV 41%、TLG 2.5、TLG 41%以及中期SUVmax均与更差EFS显著相关,并与治疗后Deauville评分相关。
- 多因素分析中,中期MTV 2.5>0 ml为EFS独立危险因素(校正HR 3.89,p=0.009)。
- 多因素分析中,中期TLG 41%≥30 g为EFS独立危险因素(校正HR 7.98,p=0.006)。
关键数值与推荐
- 中期MTV 2.5>0 ml:校正HR 3.89,p=0.009,为EFS独立危险因素。
- 中期TLG 41%≥30 g:校正HR 7.98,p=0.006,为EFS独立危险因素。
临床怎么用
- 作者认为基线与中期[18F]FDG PET定量参数可作为儿童霍奇金淋巴瘤EFS和治疗反应的预后指标。
- 作者认为这些定量指标可能有助于优化儿童和青少年霍奇金淋巴瘤的个体化、风险适应治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hodgkin lymphoma (HL) in pediatric populations has a high survival rate but poses risks for long-term morbidities. Although [18F]fluoro‑2‑deoxy‑2‑d‑glucose positron emission tomography ([18F]FDG PET) scans offer potential for improved risk stratification, the definitive prognostic value of quantitative [18F]FDG PET parameters remains unclear for pediatric HL. METHODS: A single-center, retrospective study included pediatric patients diagnosed with HL between 2016 and 2023 treated according to EuroNet-PHL-C1 and DAL/GPOH-HD protocols. Patients underwent baseline and interim PET/CT scans after two chemotherapy cycles. Event-free survival (EFS) was the primary endpoint, Deauville score was the secondary endpoint. Quantitative [18F]FDG PET parameters included SUVmax, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) that were evaluated using two segmentation methods (SUV 2.5, 41% SUVmax). Survival outcomes were assessed using Cox regression analysis. RESULTS: A total of 115 patients (50 males, median age 14.2 years) were studied, with a median follow-up period of 35 months. During this period, 16 cases (13.9%) of relapse or progression were noted. Baseline and interim MTV 2.5, MTV 41%, TLG 2.5, and TLG 41%, along with interim SUVmax, were significantly associated with worse EFS and correlated with post-treatment Deauville scores. In multivariable analysis, interim MTV 2.5 > 0 ml (adj. hazard ratio, HR: 3.89, p = 0.009) and interim TLG 41% ≥ 30 g (adj. HR: 7.98, p = 0.006) were independent risk factors for EFS. CONCLUSION: Baseline and interim [18F]FDG PET parameters can serve as significant prognostic indicators for EFS and treatment response in pediatric HL. These quantitative measures could enhance individualized, risk-adapted treatment strategies for children and adolescents with HL.
引用
- Yadgarov MY, Dunaykin MM, Shestopalov GI, et al. Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2024. PMID: 38351389. doi:10.1007/s00259-024-06643-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。